Efficacy of Surgical Systems in Combination With Phacoemulsification: a Retrospective Analysis

Launched by BARNET DULANEY PERKINS EYE CENTERS · Apr 29, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a new surgical system, called the Hydrus Microstent combined with the OMNI Surgical System, is when used alongside a common eye surgery known as phacoemulsification. This surgery is typically performed on patients with open-angle glaucoma, a condition that can lead to vision loss if not properly treated. The researchers are focusing on patients who have been using more than one medication to manage their glaucoma and have had at least three years of follow-up data after their surgery.

To be eligible for this trial, participants should be between the ages of 65 and 74 and have a history of cataract surgery with the Hydrus or OMNI systems. However, patients with certain types of glaucoma, such as angle-closure glaucoma or glaucoma caused by other conditions, cannot participate. If you join this study, you can expect to provide information about your eye pressure and medication use over the years following your surgery. This trial is still recruiting participants, so it’s a good opportunity for those who meet the criteria to contribute to important research that may help improve treatment for glaucoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects with h/o CEIOL/OMNI/Hydrus (chosen based on subjects on more than 1 medication pre-operatively) with at least 3 years of follow up data
• • have Glaucoma
• Exclusion Criteria:
• • Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
• • Patients with refractory CME or CME persisting 3 months or more post-operatively
• • Patients with incomplete IOP, medication logs or VF data within post-operative period
• • Prior incisional surgery or MIGS